Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Ovarian Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Hydralazine × Gynecologic × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00532818 2009-03-30

Hydralazine Valproate for Cervical Cancer

National Institute of Cancerología

Phase 3 Unknown
143 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00533299 2007-09-21

Hydralazine Valproate for Ovarian Cancer

National Institute of Cancerología

Phase 3 Unknown
211 enrolled
Gynecologic

Ovarian Neoplasms

NCT00404326 2006-11-28

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

National Institute of Cancerología

Phase 2 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡